Related Experiment Video

Updated: Nov 9, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.9K

DNA damage response and PD-1/PD-L1 pathway in ovarian cancer

Tianyu Zhang1, Shuangshuang Zheng1, Yang Liu1

  • 1Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, No. 154 Anshan Road, Tianjin, 300052, China; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin, 300052, China.

DNA Repair
|April 10, 2021
PubMed

Insights

DNA damage response (DDR) impacts immunotherapy efficacy in ovarian cancer. Understanding how DDR affects PD-1/PD-L1 expression can guide combination therapies and improve patient selection for better outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Ovarian cancer presents a poor prognosis due to drug resistance, relapse, and metastasis.
  • Immunotherapy shows limited efficacy as monotherapy in ovarian cancer.
  • DNA damage response (DDR) is crucial for tumor immunotherapy efficacy.

Purpose of the Study:

  • To explore the relationship between DNA damage response (DDR) and the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in ovarian cancer.
  • To identify biomarkers associated with immunotherapy efficacy and prognosis in ovarian cancer.
  • To review current advancements in PD-1/PD-L1-based immunotherapy combined with DDR-targeting therapies for ovarian cancer.

Main Methods:

  • Review of DNA damage repair pathways and their influence on PD-1/PD-L1 expression in cancer cells.
  • Identification and analysis of biomarkers affecting immunotherapy efficacy and prognosis.
  • Compilation of recent studies on combination therapies involving PD-1/PD-L1 blockade and DDR modulation in ovarian cancer.

Main Results:

  • Defective DNA repair can lead to genomic instability but also presents vulnerabilities exploitable in cancer treatment.
  • DDR mechanisms significantly influence PD-1/PD-L1 pathway expression, impacting tumor immune escape.
  • Biomarkers related to DDR are potential indicators for selecting patients who may benefit from immunotherapy.

Conclusions:

  • Understanding the interplay between DDR and PD-1/PD-L1 is vital for advancing ovarian cancer immunotherapy.
  • Combination strategies targeting both DDR and the PD-1/PD-L1 pathway hold promise for overcoming treatment resistance.
  • Further research into DDR-associated biomarkers can optimize patient stratification and therapeutic outcomes in ovarian cancer immunotherapy.
Keywords:
Combined modality therapyDNA damage responseImmune checkpoint inhibitorsOvarian cancerPD-1/PD-L1

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.0K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.3K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.7K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K